Navigation Links
Mylan Announces XELODA® Settlement and License Agreement
Date:9/21/2011

PITTSBURGH, Sept. 21, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into a settlement and license agreement with Hoffman La Roche Inc. resolving litigation related to XELODA® Tablets, 150 mg and 500 mg, USP, known generically as Capecitabine Tablets. This product is an orally administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers.

Pursuant to the agreement, the litigation was dismissed on Sept. 21, 2011.  Additional details are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. XELODA had U.S. sales of $570 million for the twelve months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

This press release includes statements that constitute "forward-looking statements," including with regard to the litigation settlement. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylans Matrix Receives Tentative FDA Approval Through PEPFAR for Novel "Co-Packaged" Version of HIV/AIDS Treatment
2. Mylan Launches Generic Version of Uroxatral® Tablets
3. Mylan Announces U.S. PTO Intends to Reissue Two Perforomist® Patents to Dey Pharma
4. Mylan Launches First Generic Version of Entocort EC® Capsules
5. Mylan Receives Approval for Generic Version of Aricept® Tablets
6. Mylan Receives Approval for Generic Version of Effexor XR® Capsules
7. Mylan Launches Generic Version of Roxicodone® Tablets
8. Mylan Launches Generic Version of Depakote® Sprinkle Capsules
9. Mylan Launches First Generic Version of Xibrom® Ophthalmic Solution
10. Mylan Launches First Generic Version of Amrix® Capsules
11. Mylan Launches Generic Version of Risperdal® M-Tab®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... is a revolutionary new product that relieves painful carpal tunnel syndrome ... affects more than 8 million people a year. Women suffer from ... methods of treating CTS are painful surgery, the use of NSAIDs ... ... a clear patch worn on the palm of the hand. It ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
(Date:7/11/2017)... Md. , July 11, 2017  The global ... estimated revenues of approximately $394.1 million in 2016.  Although ... trend of solid growth, in particular as a result ... clinical practice, and the recent introduction of a significant ... need for less-invasive testing of tumor biomarkers to guide ...
Breaking Medicine Technology:
(Date:7/28/2017)... ... , ... Kevin Harrington, one of the original Sharks from hit reality series Shark Tank, and ... campaign with My Real Earth. , Most people put their healthcare above their skincare, but ... what we put in our bodies. After all, the skin is the largest organ which ...
(Date:7/28/2017)... ... ... For over 20 years Sealy Baby has been creating crib mattresses that ... pride in using some of nature’s best materials while integrating today’s latest comfort technologies ... mattresses and crib bedding for infants and toddlers. We are thrilled ...
(Date:7/27/2017)... ... July 27, 2017 , ... Conventus, New Jersey’s ... physicians, has launched a new educational series of webinars and podcasts to guide ... prescribing of pain medication. The first two episodes of the series, entitled “Pain ...
(Date:7/27/2017)... ... July 27, 2017 , ... Patients with ... in a single office visit from Dr. Alejandro Kovacs. Dr. Kovacs is a ... East Texas patients, including Teeth-in-a-Day® dental implants in Longview, TX. ...
(Date:7/27/2017)... , ... July 27, 2017 , ... ... Verification to State Medicaid programs, Managed Care Organizations and Home Care Agencies, has ... The MEDsys platform, VinCENT, provides technology solutions to over 1,000 agencies and multiple ...
Breaking Medicine News(10 mins):